Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration

16 Aug 2024

Abstract excerpt

Enoblituzumab, an immunotherapeutic agent targeting CD276, shows both safety and efficacy in activating T cells and oligodendrocyte-like cells against various cancers. Preclinical studies and mouse models suggest that therapies targeting CD276 may outperform PD1/PD-L1 blockade. However, data from mouse models indicate a significant non-responsive population to anti-CD276 treatment, with the mechanisms of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eosinophilic Esophagitis
Share to Galectins and Cancer Biology
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39152118
DOI: 10.1038/s41467-024-51096-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltrationPMID 39152118Read ↗

Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer typesSemantic proximity Read ↗

Integrative In Silico Transcriptomic and Pharmacogenomic Analysis of CD276 as a Candidate Prognostic Biomarker and Therapeutic Target in Bladder CancerSemantic proximity Read ↗

Transcriptome Analysis and Single-Cell Sequencing Analysis Reveal the Prognostic Value and Immune Landscapes of CD276 in Pan-Cancer and Clinical Validation in GlioblastomaSemantic proximity Read ↗

ITGB6 inhibition stimulates anti-tumor responses in immunocompetent mouse models of head & neck squamous cell carcinoma and pancreatic adenocarcinomaSemantic proximity Read ↗

Functional profiling of murine glioma models highlights targetable immune evasion phenotypes.Semantic proximity Read ↗

Myeloid-specific KDM6B inhibition sensitizes Glioblastoma to PD1 blockadeSemantic proximity Read ↗

Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade.Semantic proximity Read ↗

TTC7B is a new prognostic biomarker in head and neck squamous cell carcinoma linked to immune infiltration and ferroptosisSemantic proximity Read ↗

Comprehensive Analysis of Prognosis and Immune Function of CD70-CD27 Signaling Axis in Pan-CancerSemantic proximity Read ↗

The CCL17-CCR4 axis is critical for mutant STAT6-mediated microenvironmental remodelling and therapeutic resistance in Relapsed/Refractory Diffuse Large B Cell LymphomaSemantic proximity Read ↗

Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomasSemantic proximity Read ↗

The CCL17-CCR4 Axis Is Critical for Mutant STAT6-Mediated Microenvironmental Remodeling and Therapeutic Resistance in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.